Tags

Type your tag names separated by a space and hit enter

Addition of macrolide in treating adult hospitalized community-acquired pneumonia.
Respirology. 2005 Jun; 10(3):371-7.R

Abstract

OBJECTIVES

Current clinical practice guidelines, including those in south Asia, recommend the addition of a macrolide to a broad-spectrum antibiotic for the treatment of severe hospitalized community-acquired pneumonia (CAP). The aim of this study was to observe the influence of macrolide addition on clinical outcomes of hospitalized adult patients with CAP.

METHODOLOGY

Over a 16-month period between 2002 and 2004, 141 eligible patients were prospectively recruited from an urban-based teaching hospital in Malaysia.

RESULTS

Of the 141 patients, 63 (44.7%) patients (age (standard deviation (SD)) 56 (20.0) years; 50.8% male) received a macrolide-containing antibiotic regimen, while 78 (55.3%; age (SD) 57 (20.2) years; 52.6% male) were on a single broad-spectrum antibiotic only. In total, 39 (27.7%) and 102 (72.3%) patients had severe and 'non-severe' pneumonia, respectively. Irrespective of whether they had severe or non-severe pneumonia, there were no significant differences in mortality (non-severe pneumonia, 6.5% vs. 5.4%, P = 0.804; severe pneumonia, 17.6% vs. 18.2%, P = 0.966), need of ventilation (non-severe pneumonia, 8.7% vs. 3.6%, P = 0.274; severe pneumonia, 23.5% vs. 13.6%, P = 0.425) or median length of hospital stay (non-severe pneumonia, 5.5 vs. 5 days, P = 0.954; severe pneumonia, 7 vs. 6 days, P = 0.401) between the two treatment regimens.

CONCLUSION

This observational, non-randomized study suggests that addition of a macrolide may not convey any extra clinical benefits in adult hospitalized patients with CAP.

Authors+Show Affiliations

IMU Lung Research, International Medical University, Kuala Lumpur, Malalysia. loh@imu.edu.myNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15955152

Citation

Loh, Li-Cher, et al. "Addition of Macrolide in Treating Adult Hospitalized Community-acquired Pneumonia." Respirology (Carlton, Vic.), vol. 10, no. 3, 2005, pp. 371-7.
Loh LC, Quah SY, Khoo SK, et al. Addition of macrolide in treating adult hospitalized community-acquired pneumonia. Respirology. 2005;10(3):371-7.
Loh, L. C., Quah, S. Y., Khoo, S. K., Vijayasingham, P., & Thayaparan, T. (2005). Addition of macrolide in treating adult hospitalized community-acquired pneumonia. Respirology (Carlton, Vic.), 10(3), 371-7.
Loh LC, et al. Addition of Macrolide in Treating Adult Hospitalized Community-acquired Pneumonia. Respirology. 2005;10(3):371-7. PubMed PMID: 15955152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Addition of macrolide in treating adult hospitalized community-acquired pneumonia. AU - Loh,Li-Cher, AU - Quah,Soong-Yuen, AU - Khoo,Sert-Kim, AU - Vijayasingham,Pillai, AU - Thayaparan,Tarmizi, PY - 2005/6/16/pubmed PY - 2005/10/28/medline PY - 2005/6/16/entrez SP - 371 EP - 7 JF - Respirology (Carlton, Vic.) JO - Respirology VL - 10 IS - 3 N2 - OBJECTIVES: Current clinical practice guidelines, including those in south Asia, recommend the addition of a macrolide to a broad-spectrum antibiotic for the treatment of severe hospitalized community-acquired pneumonia (CAP). The aim of this study was to observe the influence of macrolide addition on clinical outcomes of hospitalized adult patients with CAP. METHODOLOGY: Over a 16-month period between 2002 and 2004, 141 eligible patients were prospectively recruited from an urban-based teaching hospital in Malaysia. RESULTS: Of the 141 patients, 63 (44.7%) patients (age (standard deviation (SD)) 56 (20.0) years; 50.8% male) received a macrolide-containing antibiotic regimen, while 78 (55.3%; age (SD) 57 (20.2) years; 52.6% male) were on a single broad-spectrum antibiotic only. In total, 39 (27.7%) and 102 (72.3%) patients had severe and 'non-severe' pneumonia, respectively. Irrespective of whether they had severe or non-severe pneumonia, there were no significant differences in mortality (non-severe pneumonia, 6.5% vs. 5.4%, P = 0.804; severe pneumonia, 17.6% vs. 18.2%, P = 0.966), need of ventilation (non-severe pneumonia, 8.7% vs. 3.6%, P = 0.274; severe pneumonia, 23.5% vs. 13.6%, P = 0.425) or median length of hospital stay (non-severe pneumonia, 5.5 vs. 5 days, P = 0.954; severe pneumonia, 7 vs. 6 days, P = 0.401) between the two treatment regimens. CONCLUSION: This observational, non-randomized study suggests that addition of a macrolide may not convey any extra clinical benefits in adult hospitalized patients with CAP. SN - 1323-7799 UR - https://www.unboundmedicine.com/medline/citation/15955152/Addition_of_macrolide_in_treating_adult_hospitalized_community_acquired_pneumonia_ L2 - https://doi.org/10.1111/j.1440-1843.2005.00704.x DB - PRIME DP - Unbound Medicine ER -